MétaCan
Menu
Back to cohort
Record W4410811746 · doi:10.1002/jha2.70061

Efficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study

2025· article· en· W4410811746 on OpenAlexfundno aff
Yasuyuki Arai, Ruta Brazauskas, Naya He, A. Samer Al‐Homsi, Saurabh Chhabra, Minoo Battiwalla, Masamitsu Yanada, Amir Steinberg, Miguel Ángel Díaz, Sanghee Hong, Junya Kanda, Asad Bashey, Haydar Frangoul, Sherif M. Badawy, Leo F. Verdonck, Hillard M. Lazarus, Jean A. Yared, Hasan Hashem, Akshay Sharma, Mahmoud Aljurf, Ajoy Dias, Muhammad Bilal Abid, Baldeep Wirk, César O. Freytes, Amer M. Zeidan, Usama Gergis, Amer Beitinjaneh, Medhat Askar, Jeffrey J. Pu, Leslie Lehmann, Hemalatha G. Rangarajan, William A. Wood, Shahrukh K. Hashmi, Shingo Yano, Shinichi Kako, Yukiyasu Ozawa, Noriko Doki, Yoshinobu Kanda, Takahiro Fukuda, Yuta Katayama, Tatsuo Ichinohe, Junji Tanaka, Takanori Teshima, Shinichiro Okamoto, Yoshiko Atsuta, Wael Saber

Bibliographic record

VenueeJHaem · 2025
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsnot available
FundersNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchLegend BiotechMorphoSysNational Cancer InstituteServierTeijin PharmaOtsuka PharmaceuticalMeiji Seika PharmaJCR PharmaceuticalsHealth Resources and Services AdministrationSyndax PharmaceuticalsAstellas PharmaEisaiAdaptive BiotechnologiesKiadis Pharmabluebird bioOmeros CorporationVertex PharmaceuticalsAtara BiotherapeuticsActinium PharmaceuticalsRegeneron PharmaceuticalsMedical College of WisconsinPfizerNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationBeiGeneChugai PharmaceuticalNational Marrow Donor ProgramHistoGeneticsFuji PharmaGlaxoSmithKlineMallinckrodt PharmaceuticalsAstellas Pharma USNippon ShinyakuGateway for Cancer ResearchCSL BehringBristol-Myers SquibbAmgenNovartis PharmaAbbVieKyowa Hakko KirinSanofi
KeywordsTotal body irradiationMedicineInternal medicineEtoposideCytarabineHazard ratioHematopoietic stem cell transplantationCohortMyeloid leukemiaCyclophosphamideTransplantationAcute leukemiaLeukemiaGastroenterologyOncologySurgeryChemotherapyConfidence interval

Abstract

fetched live from OpenAlex

ABSTRACT Background In this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) and the United States (Center for International Blood and Marrow Transplant Research). Methods Adult patients who underwent their first myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia in remission between 2010 and 2018 using conditioning regimens of cyclophosphamide plus total‐body irradiation (CY/TBI), CY/TBI+cytarabine (AraC), or CY/TBI+etoposide (VP16) were included. Results The acute myeloid leukemia (AML) cohort (N = 480, 38.8%) indicated that overall survival (OS) was poorer in CY/TBI+AraC (hazard ratio [HR] 1.46, p < 0.001) and CY/TBI+VP16 (HR 1.39, p = 0.059) compared to CY/TBI. Relapse was not suppressed, while treatment‐related mortality (TRM) was significantly higher (HR 1.78 and 1.74, p < 0.001 and 0.018, respectively). In the acute lymphoblastic leukemia (ALL) cohort (N = 3901, 61.2%), OS was comparable among these regimens. With intensified regimens, relapse was significantly suppressed in CY/TBI+VP16 (HR 0.74, p = 0.005), while TRM was higher (HR 1.21, p = 0.077). No interactions were observed regarding the country. Conclusion In AML adding AraC and VP16 to CY/TBI had an adverse effect on OS. Conversely, in ALL, adding VP16 or AraC to CY/TBI did not affect survival, but the addition of VP16 reduced the risk of relapse. Clinical Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.026

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.352
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueeJHaemSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207